Investigation of the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs S 524101 (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- Sponsors Stallergenes SA
- 28 May 2014 Planned End Date changed from 1 Dec 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 09 Sep 2013 Tolerability results presented at the 23rd Annual Congress of the European Respiratory Society.
- 13 Aug 2013 Planned number of patients changed from 64 to 96 as reported by ClinicalTrials.gov record.